- 8 Nov 2019 Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting
- 3 Oct 2019 Kymab Announces Presentation on KY1049 at the European Congress on Thrombosis and Haemostasis
- 27 Sep 2019 Kymab outlines positive new findings for its KY1044 Anti-ICOS program at the CICON 2019 Annual Meeting
- 16 Jul 2019 Kymab Appoints Catherine Moukheibir as Non-Executive Director
- 13 Jun 2019 Kymab Announces Presentations at the 24th EHA Annual Congress
- 1 Jun 2019 Kymab Poster on Adaptive Phase 1/2 Clinical Trial for KY1044 anti-ICOS Program at 2019 ASCO Meeting
- 8 Apr 2019 Kymab appoints Simon Sturge as Chief Executive Officer
- 30 Nov 2018 Kymab granted leave to appeal to the UK Supreme Court
- 28 Jun 2018 Kymab and Roche clinical trial agreement for KY1044
- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019
KY1043, a bifunctional, PD-L1-based, IL-2Rα (CD25)-directed immunocytokine, binds and blocks the activity of PD-L1 on PD-1 and pre...
Read article
Featured article: Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
LifeArc will make a US$30 million equity investment in Kymab LifeArc to gain access to IntelliSelect platforms to enhance ...
Read article